D. Boral Capital lowered the firm’s price target on Quince Therapeutics (QNCX) to $4 from $12 and keeps a Buy rating on the shares. The firm balanced its optimism around the company’s trial data with concerns about financing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX: